European committee takes a second look at Alzheimer’s drug and now says it should be approved
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug.
EU drugs regulator recommends Alzheimer's drug from Eisai-Biogen
The European Union's drugs regulator on Thursday said it recommends approval of Eisai and Biogen's Leqembi in patients with early Alzheimer's disease, months after the agency first rejected the treatment.
Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug
Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease drug that the company developed with Japanese partner Eisai — reversing an earlier decision not to approve the drug.
EU regulator reverses decision to block Alzheimer's drug lecanemab
The European Union's drugs regulator reversed its decision to block the Alzheimer's drug lecanemab, a treatment aimed at slowing cognitive decline in patients. In July, the Amsterdam-based European Medicines Agency (EMA) denied recommending approval of the drug made by Eisai and Biogen because it considered the risks - especially bleeding and swelling in the brain - to be greater than the potential benefits in a broad population.
EU regulator backs Eisai-Biogen Alzheimer's drug after initial rejection
The European Union's drugs regulator on Thursday recommended approval for Eisai and Biogen's Leqembi in some patients with early Alzheimer's disease, nearly four months after it first rejected the treatment.
European Watchdog Partially Approves New Alzheimer's Drug
Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer's disease, reversing an earlier decision not to give it the green light.
Changing course, European regulators now say Alzheimer’s treatment Leqembi should be approved
Reversing an earlier decision, European regulators recommended that an Alzheimer’s therapy from Eisai and Biogen should be approved.
ScienceAlert on MSN16h
Brain Autopsies Reveal a Potential New Culprit Behind Alzheimer's
University of Washington-led research, published in 2023, discovered microglia in the brains of people with Alzheimer's ...
Caring for N.Y.ers with Alzheimer’s
November is Alzheimer’s Awareness Month and New York has the second highest rate of Alzheimer’s disease in the U.S. NYC’s ...
Healthier Together: New Alzheimer’s disease warning signs to look out for
A breakthrough in the fight against Alzheimer’s disease may have been made in Seattle. Researchers at the Allen Institute ...
Nasal Spray Could Delay Alzheimer's by Years
An anti-Alzheimer's nasal spray that could delay the progress of the disease by years has been developed by scientists at ...
Richmond2hOpinion
Commentary: How to fight the stigma of Alzheimer's and dementia
Having a loved one with Alzheimer’s is incredibly taxing, both emotionally and physically. It’s OK to ask for help.
'We are very hopeful' | New nasal spray could delay Alzheimer's by years, researchers say
Researchers at Texas A&M University have developed a nasal spray shown to delay disease progression in animals -- fueling ...
Alzheimer’s caregivers need updated drug rules to give families more time and peace | Opinion
Alzheimer’s disease robs patients of so much more than their health. It can rewire their personalities and undermine a ...
Alzheimer's Disease Month - Helping Those Living with the Disease
November is National Alzheimer’s Disease Month, and it’s also Caretaker Month. These two things often go hand-in-hand, but ...
Medscape17h
Infection Plus Pollution Equals Increased Alzheimer’s Risk
The AD risk factors/hits include high exposure to traffic-related air pollution (TRAP) and infections, as well as factors ...
New drug targets for Alzheimer's identified from cerebrospinal fluid
A multitude of genes have been linked to the development of Alzheimer's disease. Specifically how those genes might influence ...